The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells by Urszula Daniluk et al.
Daniluk et al. Journal of Experimental & Clinical Cancer Research 2012, 31:69
http://www.jeccr.com/content/31/1/69RESEARCH Open AccessThe peptide derived from the Ig-like domain of
human herpesvirus 8 K1 protein induces death in
hematological cancer cells
Urszula Daniluk1,2†, Celine Kerros1†, Rong-Hua Tao1, Jillian F Wise1, Xue Ao1, Zuzana Berkova1*,
and Felipe Samaniego1,3Abstract
Background: Although significant progress has been made in the treatment of lymphomas, many lymphomas
exhibit resistance to cell death, suggesting a defective Fas signaling, which remains poorly understood. We
previously reported that cells expressing the K1 protein of human herpesvirus 8 (HHV-8) resist death through the
complex formation of the Ig-like domain of K1 with Fas. Recently, we investigated whether peptides derived from
the Ig-like domain of the K1 protein may affect cell death.
Methods: K1 positive and negative cell lines were incubated with the K1-derived peptides, and cell death
(apoptotic and necrotic) was assessed by flow cytometry and LDH assay. Activation of caspases was assessed by
fluorometric assay and flow cytometry. Fas receptor-independent, peptide-mediated cell killing was tested in the
Fas-resistant Daudi cell line and Jurkat cell clones deficient in caspase-8 and FADD functionality. Activation of TNF
receptors I and II was blocked by pre-incubation with corresponding blocking antibodies. The effect of the K1
peptide in vivo was tested in a mouse xenograft model.
Results: We observed that the peptide S20-3 enhanced cell death in K1-positive BJAB cells and HHV-8 positive
primary effusion lymphoma (PEL) cell lines. Similar effects of this peptide were observed in B-cell lymphoma and
T-lymphoblastic leukemia cells without K1 expression but not in normal human peripheral blood mononuclear cells.
A single intratumoral injection of the S20-3 peptide decreased the growth of Jurkat xenografts in SCID mice. The
mechanism of tumor cell death induced by the S20-3 peptide was associated with activation of caspases, but this
activity was only partially inhibited by the pan-caspase inhibitor z-VAD. Furthermore, the K1 peptide also killed
Fas-resistant Daudi cells, and this killing effect was inhibited by pre-incubation of cells with antibodies blocking
TNFRI.
Conclusion: Taken together, these findings indicate that the S20-3 peptide can selectively induce the death of
malignant hematological cell lines by Fas- and/or TNFRI-dependent mechanisms, suggesting the K1-derived
peptide or peptidomimetic may have promising therapeutic potential for the treatment of hematological cancers.Background
The key to effective chemotherapy responses in cancer
is the presence of the Fas receptor (CD95, Apo-1), a
member of the tumor necrosis factor superfamily of cell
death receptors [1]. These receptors form trimers in the
plasma membrane and, upon the binding of their* Correspondence: ZBerkova@mdanderson.org
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reproduction in any medium, provided the orrespective ligands, activate the initiator caspase-8
through the recruitment of adaptor proteins (FADD and/
or TRADD) to the receptors’ death domains. In type I
apoptosis, the activated caspase-8 directly activates exe-
cutioner caspases. In type II apoptosis, caspase-8 cleaves
Bid triggering permeabilization of the mitochondrial
outer membrane, cytochrome C release, and propagation
of the apoptotic signal downstream of the cascade [1].
Many studies suggest that drug-induced apoptosis
occurs through Fas signaling; thus, defective Fas signal-
ing could be responsible for the resistance toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[2-5]. Several studies have shown that the Fas-mediated
cell-death pathway is altered in malignant hematological
cells [6,7], which can be viewed as one of the mechan-
isms of resistance to chemotherapy. The CD44 isoforms
v6 and v9, hepatocyte growth factor receptor/Met
(HGFR/Met), and HHV-8 oncoprotein K1 have been
shown to bind to Fas and regulate its activity [8-11].
Therefore, treatments targeting these Fas regulators in
cancer cells could be an effective strategy to increase sen-
sitivity to Fas-mediated apoptosis and to chemotherapy.
Lymphomas occur frequently in association with infec-
tious agents such as the Epstein-Barr virus, human im-
munodeficiency virus, or HHV-8 [12,13]. We have
shown that the HHV-8-derived K1 protein interacts with
Fas and blocks apoptosis [8,10]. In the current study, we
investigated whether peptides derived from the Ig-like
domain of the K1 protein could alter K1-Fas interaction
and, consequently, apoptosis in lymphoma cells. For this
purpose, we treated K1-expressing cells as well as B-cell
lymphoma and T-lymphoblastic leukemia cells with pep-
tides corresponding to the Ig-like domain of K1, fol-
lowed by cell death analysis. Our results show that the
K1-derived S20-3 peptide kills lymphoma and leukemia
cells in vitro and in vivo by a mechanism dependent on
Fas and/or TNF-α receptors.
Methods
Cells
Human lymphoblastoma cell lines BJAB, Daudi; HHV-8-
positive primary effusion lymphoma-derived B-cell lines
BC-3, BCBL-1, KS-1; human T-lymphoblastic cell line Jur-
kat (all from ATCC, Manassas, VA), a caspase-8– and
FADD–deficient Jurkat cell lines (I9.2 and I2.1) (donated
by Dr. J. Chandra, The University of Texas MD Anderson
Cancer Center) were grown in RPMI 1640 medium sup-
plemented with 10% FBS (both from Mediatech, Herndon,
VA) and maintained in a 5% CO2 atmosphere at 37°C.
The 293T cells (ATCC) were cultured in Dulbecco’s modi-
fied Eagle's medium (DMEM) (Mediatech) supplemented
with 10% FBS. Collection of blood samples was in accord-
ance with approved MD Anderson Cancer Center proto-
col. Peripheral blood mononuclear cells (PBMCs) from
healthy volunteers were isolated from heparinized venous
blood by density gradient centrifugation and used imme-
diately in the experiments. BJAB cells stably expressing K1
(BJABK1) were described previously [8,10].
Peptide synthesis
Peptides were chemically synthesized by multiple pep-
tide solid-phase synthesis (New England Peptide,
Gardner, MA, and Celtek Bioscience, Nashville, TN). All
peptides were purified to >95% purity by high-
performance liquid chromatography. Peptide stocks(10 mM) were prepared in dimethyl sulfoxide (DMSO)
(Thermo Fisher, Waltham, MA), and aliquots were
stored at −20°C.
Apoptosis analysis
Apoptosis analysis was performed using the FITC
AnnexinV Apoptosis Detection Kit I, according to the
manufacturer’s protocol (BD Biosciences, San Jose, CA).
Cells were re-suspended in serum-free medium (1 × 106/
mL) and treated with either 100 μM peptide alone or
combined with 20 μM z-VAD (BD Biosciences) for
1 hour, or pretreated for 15 minutes with the peptide
and combined with 200 ng/mL of recombinant soluble
Fas ligand (FasL) (Alexis, San Diego, CA) for the
indicated times. Subsequently, cells were washed, re-
suspended in a binding buffer containing AnnexinV-
FITC and propidium iodide (PI), and analyzed by flow
cytometry (FACSCalibur; Beckman-Coulter, Brea, CA)
after 15 minutes of incubation.
Caspase activity assay
The activities of caspase-8, -9, and -3 were determined by
flow cytometry using the CaspGLOWTM Fluorescein Ac-
tive Caspase Staining Kit (BioVision, Mountain View,
CA), according to the specifications of the manufacturer.
Briefly, 1 × 106 cells were seeded in serum-free medium
and treated with 100 μM S20-3 peptide for 1 hour. Cells
were then washed, cultured in medium containing 10%
FBS for 3 hours, and, subsequently, incubated with 1 μl of
FITC-IETD-FMK (for caspase-8 activity), FITC-LEHD-
FMK (for caspase-9 activity), or FITC-DEVD-FMK (for
caspase-3 activity) for 60 minutes at 37°C. Cells were
washed twice and analyzed by flow cytometry.
Immunoblotting
The cells (10 × 106) were resuspended in 1 mL of lysis
buffer (Cell Signaling Technology, Beverly, MA) supple-
mented with protease inhibitors (Roche), and incubated
1 hour on ice. One hundred micrograms of each extract
were separated on 10% SDS-polyacrylamide gels (Bio-
Rad Laboratories, Hercules, CA) and transferred to
nitrocellulose membranes (Whatman Schleicher &
Schuell, Keene, NH). Membranes were blocked at room
temperature for 1 hour in blocking buffer (5% nonfat dry
milk, 0.1% Tween-20 in PBS). Separated proteins were
analyzed by Western blot with anti-GAPDH (1:1000,
Santa Cruz Biotechnology, Santa Cruz, CA; loading con-
trol), anti-TNFRI and anti-TNFRII antibodies (1:1000,
both kind gifts from Dr. B. B. Aggarwal, MD Anderson
Cancer Center) overnight at 4°C. Blots were washed and
then incubated with either anti-mouse (Santa Cruz
Biotechnology) or anti-rabbit (Cell Signaling Technology)
horseradish peroxidase-conjugated antibody (1:5000).
The signal was visualized by chemiluminescence
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posure to film (Amersham, Piscataway, NJ).
LDH assay
Cells (1 × 106) were pre-incubated for 1 hour with 5 μg/
mL of TNFRI or TNFRII blocking antibodies (both from
R&D Systems, Minneapolis, MN) at 37°C and then trea-
ted with TNF-α (10 ng/mL) (Life Technologies - Gibco,
Carlsbad, CA) or the peptide S20-3 (100 μM) for 1 hour.
After treatment, the growth medium was removed and
stored at −20°C. An LDH assay was performed accord-
ing to the manufacturer's protocol (BioVision). Standard
media were used as blank controls; “high control” corre-
sponds to the sample of cells treated with lysis solution.
Results were normalized to control cells, and the per-
centage of necrotic cells was calculated using the follow-
ing formula: % cytotoxicity = [(treated– control)/(high
control– control)] × 100.
In vivo tumor growth assay
All animal studies were conducted according to protocols
approved by MD Anderson Cancer Center’s Institutional
Animal Care and Use Committee. Jurkat cells (5× 106 per
injection) were re-suspended in sterile PBS and subcuta-
neously injected into the right flank of 5-week-old CB17/
SCID mice (Harlan Laboratories, Indianapolis, IN). When
xenograft tumors reached 100 mm3, the mice were given a
single intratumoral injection of peptides (33.9 mg/kg):
S20-3, TCR, or vehicle; 4 mice each. The mice were killed
8 days after injection, and the tumor tissue was harvested.
Tumor width (W) and length (L) were measured by cali-
pers, and size was calculated using the formula W2× L/2.
The tumoricidal activity was evaluated by comparison of
tumor size among groups.
Statistical analysis
The 2-tailed Student’s t test was used to estimate the
statistical significance of the differences between results
from triplicate samples or experiments, and the results
are expressed as mean values ± standard deviations or
standard errors, respectively. The level of significance
was set at P < 0.05.
Results
S20-3 peptide induces cell death of BJABK1 cells
Our previous studies demonstrated that wild-type K1,
but not a truncated K1 with the Ig-like domain deleted,
binds to Fas and prevents Fas activation by FasL or by
an agonistic Fas antibody [8,10]. To further elucidate
K1-mediated regulation of Fas, we designed peptides
derived from the Ig-like domain of K1 (Table 1), target-
ing the K1 binding site on the Fas receptor.
We first investigated whether K1 peptides could
sensitize the Burkitt’s lymphoma cell line BJAB stablyexpressing K1 (BJABK1) to Fas-mediated apoptosis. Cells
were treated with 100 μM peptide in combination with
200 ng/mL of FasL for 24 hours, followed by analysis of
apoptosis by flow cytometry. The combination of S20-3
and S10-1 peptides with FasL showed a significant (2.2-
and 2.5-fold, respectively) increase in cell death
compared with FasL alone (Figure 1A). No significant
differences in apoptosis rates were seen with FasL in
combination with other K1-derived peptides shown in
Table 1 (20–1, 20–2, S10-2, S8-1, S8-2).
In the control experiment, BJABK1 cells were treated
with 100 μM peptides or buffer for 1 hour, and apoptosis
was evaluated 24 hours after treatment by flow cytome-
try. Surprisingly, two of the longest overlapping peptides
(S20-2 and S20-3) individually induced a significant (1.9-
and 2.4-fold, respectively) increase in apoptotic cell
death in the BJABK1 cells compared with buffer control
(Figure 1B). None of the other peptides overlapping the
20-amino acid sequence of the peptide S20-3 (Table 1)
showed a significant apoptotic effect.
The S20-3 peptide showed a reproducible, dose-
dependent increase in apoptotic cell death (up to 40% at
100 μM) as early as 4 hours after treatment, while the
control peptide S8-2 was ineffective at all tested concen-
trations (Figure 1C). Further studies were performed to
understand the underlying mechanism for the induction
of cell death by the S20-3 peptide.
The proper control for the peptide activity would have
been a scrambled S20-3-derived peptide. However, we
encountered difficulty obtaining reasonable quantities of
any S20-3-derived scrambled peptide of desired purity
(>95%), suitable for the experiments. One possibility was
to use inactive 20-mer peptide S20-1 as a negative con-
trol, but this peptide does not share any residues with
the active S20-3 peptide. Based on the results in
Figure 1A and B, the S8-2 peptide, which overlaps part
of S20-3 peptide, was included as negative control re-
agent in subsequent studies.
The S20-3 peptide activates caspases and triggers
apoptosis in BJABK1 cells
Stimulation of the Fas death receptor results in the re-
cruitment of the adaptor protein, FADD, and activation
of caspase-8, which initiates propagation of the death
signal down the caspase cascade [14,15]. To determine
the involvement of caspase-8, -9, and -3 in the cell death
induced by the S20-3peptide, we used caspase-specific
fluorescently-tagged substrates to monitor caspase acti-
vation. In the BJABK1 cells, exposure to S20-3 signifi-
cantly (P < 0.01) increased the activity of all caspases
tested: caspase-8 (39.6% vs. 3.7%), caspase-9 (78.3% vs.
7.4%) and caspase-3 (75.2% vs. 10.2%) (Figure 1D). These
findings indicate the role of the caspase-8–initiated
apoptotic pathway in S20-3 peptide-induced cell death.
Table 1 Protein sequence of the Ig-like domain of human herpesvirus 8 K1 protein and derived peptides
K1 Ig-domain HSLWITWYPQPVLQTLCGQPSNTVTCGQYVTLYCSTSGNYVTVW
K1 peptides
20 amino acids S20-1 HSLWITWYPQPVLQTLCGQP (84–103)
S20-2 PVLQTLCGQPSNTVTCGQYV (94–113)
S20-3 SNTVTCGQYVTLYCSTSGNYV (104–124)
10 amino acids S10-1 SNTVTCGQYV (104–113)
S10-2 TVTCGQYVTL (106–115)
8 amino acids S8-1 TVTCGQYV (106–113)
S8-2 VTLYCSTS (113–120)
Daniluk et al. Journal of Experimental & Clinical Cancer Research 2012, 31:69 Page 4 of 12
http://www.jeccr.com/content/31/1/69The control S8-2 peptide showed no effect on caspases’
activity (Figure 1D).
Another important feature of apoptosis is a decrease
of the mitochondrial membrane potential (Ψm) [16].
Changes in the Ψm in cells exposed to peptides S20-3
and S8-2, or the agonistic Fas antibody CH-11 asFigure 1 A human herpesvirus 8 K1 peptide induces dose-dependent
cells were pulse-treated for 1 hour with 100 μM concentration of indicated
concentration of the indicated peptide alone (B), and increasing concentra
in a complete medium for 24 hours, stained with AnnexinV/PI, and examin
peptide or DMSO for 1 hour. The cells were then washed and incubated in
analyzed by flow cytometry. The results are presented as means ± SD of trip
compared with control treatment; *P< 0.05.positive control, were measured by staining with tetra-
methylrhodamine ethyl ester (TMRE). A decreased
TMRE signal corresponding to decreased membrane po-
tential was observed in a significant number of S20-3
peptide-treated (20%) and CH-11–treated (22%) cells
as early as 4 hours after treatment, relative to treatmentcell death and activates caspase cascade in BJABK1 cells. BJABK1
Ig-like domain-derived peptides and 200 ng/mL of FasL (A), 100 μM
tions of S20-3 or S8-2 peptides (C). Cells were, subsequently, incubated
ed by flow cytometry. (D) BJABK1 cells were treated with 100 μM
complete medium for 4 hours. Fluorometric caspase activity was
licate wells. Asterisks indicate statistically significant differences
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Figure S1).
The S20-3 peptide is effective against various
hematological cancer cell lines
We further investigated whether the S20-3 peptide
would be effective in inducing cell death in HHV-
8–positive cancer cell lines (KS-1, BC-3, BCBL-1), which
have been shown to express K1 [10]. All HHV-
8–infected cell lines tested were sensitive to the S20-3
peptide, which induced death in about 20–35% of cells,
whereas no significant effect on cell death was detected
with the S8-2 control peptide (Figure 2A).
To evaluate whether the peptides were able to modu-
late the interaction between Fas and K1, 293T cells were
transiently transfected with the vector expressing Flag-
tagged K1 protein, lysed, and subjected to co-
immunoprecipitation analysis used previously to show a
direct physical interaction of Fas with K1 [8]. We
observed that K1-Fas interaction was not disrupted by
incubation of cells with the S20-3 or other K1-derived
peptides with the exception of the shorter peptide S10-1
(Additional file 1: Figure S2).
The lack of S20-3 peptide’s effect on the K1-Fas inter-
action suggested a possible cell-killing mechanism inde-
pendent of K1. To confirm this hypothesis, we tested the
peptide’s ability to kill K1-negative cell lines. The S20-3
peptide was able to induce significant levels of cell death
in K1-negative BJAB cells (30%) and in the T-cell
leukemia Jurkat cell line (25%) (Figure 2B). Quite sur-
prisingly, the S20-3 peptide was equally effective in kill-
ing Daudi cells (35%), which express low levels of Fas on
the cell surface and are considered Fas-resistant [17].
In contrast, human PBMCs from healthy donors, trea-
ted with S20-3 peptide, showed no significant amount of
cell death (Figure 2C). Overall, S20-3 peptide treatment
induced a 4.6 ± 1.6% increase in cell death in 3 PBMC
control samples from different donors, whereas the same
treatment induced a 23.8 ± 5.7% increase in death of Jur-
kat cells. These results suggest that the S20-3 peptide
derived from the HHV-8 K1 protein selectively induces
cell death in malignant hematological cells, but is not
toxic to normal human cells.
The S20-3 peptide kills cells in the absence of the Fas
receptor
To investigate whether S20-3–induced apoptosis
depends on the signaling of the Fas receptor, we tested
the S20-3 peptide in Fas-resistant Jurkat cell lines I2.1
and I9.2, which have defective FADD and caspase-8
functions, respectively [18]. The S20-3 peptide induced
slightly less cell death in I2.1 cells than in the wild type
Jurkat cells (21% vs. 24% above control; Figure 3A). The
response of caspase-8 function-defective Jurkat cell lineI9.2 to the S20-3 peptide was significantly blunted com-
pared with that of wild-type Jurkat cells (14.4% vs. 24%
above control; 60% reduction) but not completely elimi-
nated (Figure 3A). In line with this result, we found that
the pan-caspase inhibitor z-VAD also only partially
blocked S20-3-induced death in BJAB cells (8.9% vs.
13.3% above control; 67% reduction) (Figure 3B) as well
as apoptosis induced by the Fas-agonistic antibody CH-
11 (14% vs. 29% above control; 48% reduction) (data not
shown).
Further examination of the cell death induced by the
S20-3 peptide in Daudi cells revealed that the S20-3 peptide
induced necrosis (33.7% PI–positive cells) rather than
apoptosis (0.3% AnnexinV–positive/PI–negative cells) in
Fas-resistant Daudi cells (Figure 3C and Additional file 1:
Figure S3A), and z-VAD further enhanced this effect
(41.1% PI–positive cells) (Figure 3C). An LDH release assay
further confirmed that the S20-3 peptide was causing ne-
crosis as early as 1 hour post treatment (Additional file 1:
Figure S3B).
Cell killing by the S20-3 peptide involves TNF-α receptors
The fact that the S20-3 peptide induced necrosis of Fas-
resistant Daudi cells, together with the observed rapid
kinetics of cell killing (significant cell death at 4 hours),
pointed to the possibility that the S20-3 peptide is pro-
miscuous and interacts not only with Fas, but it may also
engage one of the closely related death receptors sharing
a significant structural similarity [19]. Such promiscuity
is not unprecedented. For example, IFN-α–treated Daudi
cells upregulate expression of TNF-α and Fas. Produced
TNF-α then activates the closely related Fas receptor
[20]. Based on these facts, we hypothesized that a pep-
tide designed to bind Fas receptor may also interact with
and affect the TNF receptor.
We first evaluated the expression levels of TNFRI and
TNFRII in BJAB, Jurkat, and Daudi cells and found that
all 3 cell lines expressed TNFRI, but only BJAB and Daudi
cells expressed detectable levels of TNFRII (Figure 4A).
We next evaluated the effect of TNFR-blocking antibodies
on necrosis induced by TNF-α or S20-3 peptide by meas-
uring LDH release as early as 1 hour after treatment to
evaluate necrosis/necroptosis rather than post-apoptotic
secondary necrosis [21]. Figure 4B clearly shows that pre-
incubation of Daudi cells with the TNFRI blocking anti-
body decreased TNF-α and S20-3 peptide induced necro-
sis/necroptosis, while the TNFRII-blocking antibody
showed a rather enhanced killing. The latter finding is
consistent with the inhibition of pro-survival signaling
mediated by TNFRII [22] by the blocking antibody. These
results suggest that, besides Fas, TNFRI is also targeted by
S20-3. We then tested the effect of TNFRI-blocking anti-
body on peptide-induced necroptosis in TNFRI-positive
BJABK1 and BJAB cells. In both cell lines, the TNFRI-
Figure 2 The HHV-8 K1-derived peptide S20-3 induces cell death in K1-positive and K1-negative hematological cancer cells but not in
PBMCs from healthy donors. Indicated cell lines (1 × 106 cells/mL) were incubated with 100 μM peptide S20-3 or buffer for 1 hour. Cells were
washed and incubated in complete medium for 24 hours before flow cytometry analysis. (A) HHV-8– and K1-positive cell lines KS-1, BC-3, BCBL-1;
(B) HHV-8 and K1-negative cell lines BJAB, Jurkat, Daudi; (C) Jurkat cells and PBMCs from healthy donors. Data in (A) and (B) are shown as the
means ± SD of triplicate wells. Double asterisks indicate significant differences compared with control treatments; **P< 0.01. Panel (C) shows
representative results of 2 experiments with samples analyzed in triplicates.
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Figure 3 The S20-3 peptide–induced cell death is only partially dependent on caspases and involves necroptosis. (A) Jurkat (wild-type),
Jurkat I9.2 (caspase-8–deficient), and Jurkat I2.1 (FADD-dominant-negative mutant) cell lines were incubated with 100 μM peptide S20-3. (B) BJAB
cells were incubated with 100 μM peptide S20-3 in the presence or absence of 20 μM pan-caspase inhibitor z-VAD-FMK. (C) Daudi cells were
incubated with 100 μM peptide S20-3 or buffer in the presence or absence of 20 μM pan-caspase inhibitor z-VAD-FMK. After 1 hour of
incubation, cells were washed and incubated in complete medium for 24 hours before flow cytometry analysis. Data in (A) and (B) are shown as
means ± SD of triplicate wells; *P< 0.01.
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by TNF-α and S20-3 peptide (Figure 4C). However, the
TNFRI-blocking antibody-mediated inhibition of cell-
killing was more prominent in BJABK1 cells, where the
S20-3 peptide binding to Fas is blocked by K1 (a lack of
displacement of K1 from Fas by S20-3 peptide; Add-
itional file 1: Figure S2). Thus, in this case, the peptide acts
primarily on TNFRI. On the other hand, TNFRI-blocking
antibody affected cytotoxicity of TNF-α and S20-3 peptide
to a lesser extent in BJAB cells, consistent with the avail-
ability of Fas for peptide S20-3 binding in the absence of
K1 and, thus, for primary peptide signaling effects.
The S20-3 peptide corresponds to the Ig-like domain
of K1 and shares the conserved residues with other Ig-
like domains (Figure 5A). To further explore structure-
related promiscuity, we tested a 20–amino acid peptide
derived from the Ig-like domain of the human T-cell re-
ceptor (TCR) (Figure 5A), homologous to the peptide
S20-3 from K1. Both peptides share 5amino acid resi-
dues common to the Ig-like domains and exhibit high
hydrophobicity. The TCR peptide showed 60–80% of
the cell death-inducing activity of the S20-3 peptide in 3
independent experiments (Figure 5C), furtherunderscoring a mechanism involving possible structural
promiscuity of peptides and/or receptors.Inhibition of tumor growth by the S20-3 peptide in a
xenograft model
The SCID mice injected subcutaneously with Jurkat cells
developed solid tumors at the inoculation site. Using this
model, we tested the ability of the peptide S20-3 to alter
growth of xenograft tumors. Mice received a single
intratumoral injection of vehicle, S20-3, or TCR peptide.
Treatment with the S20-3 peptide resulted in a modest
but significant (P < 0.05) suppression of tumor growth
8 days after injection compared with vehicle control
(Figure 5D). In line with our in vitro results, the TCR
peptide showed a smaller suppressive effect on tumor
growth, without statistical significance. Importantly, the
mice treated with the peptides did not exhibit signs of
toxicity, such as agitation or impaired movement and
posture. These results support intratumoral administra-
tion of the S20-3 peptide as a potentially safe approach
for inducing significant inhibition of xenograft tumor
growth.
Figure 4 The S20-3 peptide–induced cell death involves TNFRI. (A) Immunoblot analysis of total cellular levels of TNF receptors I and II in
BJAB, Jurkat, and Daudi cells. Numbers represent expression levels relative to GAPDH (loading control). (B) Daudi cells were pre-incubated for
1 hour with 5 μg/mL of TNFRI- or TNFRII-blocking antibodies, followed by 1 hour of treatment with 5 ng/mL of TNF-α or 100 μM peptide S20-3,
and immediately analyzed for necrosis by LDH release assay. (C) BJABK1 cells (left panel) and BJAB cells (right panel) were pre-incubated for
1 hour with 5 μg/mL of TNFRI-blocking antibody, subsequently treated with 100 μM peptide S20-3 or 5 ng/mL of TNF-α for 1 hour, and analyzed
as in (B). The relative cytotoxicity values in (B) and (C) were calculated as LDH release in [(treated-control)/(high control-control)]x100 and are
shown as means ± SD of triplicate wells; *P< 0.005, **P< 0.02.
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In this report, we present evidence showing that the
peptide S20-3, corresponding to the Ig-like domain of
the Fas-targeting K1 protein of HHV-8, selectively kills
hematological cancer cells, and the mechanism involves
the Fas and TNFRI receptors. The cell-killing effect
appears to be selective for cancer cells in vitro. In vivo,even a single intratumoral dose of peptide was active
against the growth of xenograft tumors.
From the array of K1 Ig-like domain peptides tested
(Table 1), only the S20-3 peptide demonstrated strong
and reproducible cell-killing activity (Figure 1 and
Figure 2) in all 6 hematological cell lines tested but not
in PBMC controls (Figure 2). While it is not clear as to
Figure 5 The S20-3 peptide, but not the structurally similar TCR-derived peptide, significantly suppresses growth of Jurkat cell
xenografts. (A) Sequence alignment of the relevant regions of the Ig-V domains based on the known structures (http://www.ncbi.nlm.nih.gov/
Structure/cdd/cddsrv.cgi?hslf=1&uid=cd00099&#seqhrch) and the sequence comparison of S20-3 with the corresponding human TCR-α-derived
peptide. (B) Predicted structures of S20-3, S10-2, and S8-2 peptides extracted from the structure of TCR-α (Protein Database ID 1FYT) using Cn3D
4.3 software (www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml). (C) Jurkat cells were treated with 100 μM peptides (S20-3, TCR) or buffer for
1 hour and, subsequently, incubated in complete medium for 24 hours. Cell killing was analyzed by flow cytometry, and background death
(buffer) was subtracted. Values are presented as the means of the percentage of activity relative to the activity of S20-3 ± SE from 3 independent
experiments. (D) Flanks of SCID mice were injected with 5 × 106 Jurkat cells. Two weeks later, tumors were injected with a single dose of S20-3,
TCR peptide, or vehicle (DMSO) in 50 μL of saline (4 mice each). Eight days after treatment, mice were killed and the tumors were harvested and
measured. Tumor measurements are reported as means ± SD; *P< 0.05.
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other K1 Ig-like domain-derived peptides, possess cell-
killing activity, the structural features of the predicted
Ig-domain (Figure 5B) reveal a unique feature of the
S20-3 peptide; a loop (centered at conserved glycine resi-
due) linking 2 beta sheets, which are predicted to be
destabilized or absent in the rest of peptides tested
(Table 1). A truncated version of the S20-3 peptide, S10-
1, representing the first beta sheet and the loop
(Figure 5B), as well as S8-2 peptide, representing the sec-
ond beta sheet (Figure 5B), lack cell killing properties
(Figure 1B). On the other hand, a TCR-derived peptide
sharing 5 structure-defining residues with S20-3
(Figure 5A) also showed cell-killing effect (Figure 5C),suggesting that the biological effect of S20-3 is related to
its structure.
A seemingly contradictory effect of the whole Ig-like
domain in K1 protein and S20-3 peptide on Fas signaling
may also be explained by the structure-function relation-
ship. The fact that peptide S10-1, but not S20-3 or any
other K1 peptide, was able to disrupt the K1-Fas com-
plex (Additional file 1: Figure S2) suggests that first beta
sheet is involved in K1-Fas interaction. This is further
supported by the fact that peptide S10-2, lacking 3 resi-
dues from the first beta sheet, failed to displace K1
(Additional file 1: Figure S2) and did not show any en-
hancement of FasL activity (Figure 1A). Additionally,
peptide S20-2, which also contains S10-1 residues,
Daniluk et al. Journal of Experimental & Clinical Cancer Research 2012, 31:69 Page 10 of 12
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but with reduced reproducibility, suggesting that the sec-
ond beta sheet in peptide S20-3 increases structural sta-
bility of the peptide and the additional residues,
preceding (S20-2) or following (S20-3) S10-1 region,
affect peptide behavior. Taking all this into account, we
hypothesize that the smaller size and possible flexibility
of the loop within S10-1peptide as compared to S20-3
peptide (Figure 5B) allow access of this peptide to the
K1 binding site and, thus, displacement of K1 from Fas
(Additional file 1: Figure S2). The second beta sheet in
the S20-3 peptide stabilizes the loop, but at the same
time, it decreases loop flexibility and increases bulkiness
of the peptide, limiting its access to the K1 binding site
in the presence of the K1 protein.
This hypothesis also helps explain the differential
effects of the K1 Ig-like domain, S10-1, and S20-3 on
Fas receptor activation. The S10-1 sequence within the
Ig-like domain in the whole K1 protein is flanked by
additional domains of K1 protein. Assuming the S10-1
region within K1 is exposed and available to bind Fas,
the limitations of the movement imposed by surround-
ing K1 domains “lock” the Fas receptor in the closed
conformation, preventing binding of FasL described
previously [8]. On the other hand, the beta sheet and
flexible loop in the S10-1 peptide can also bind the re-
ceptor, but without the rigidity of surrounding struc-
tures, its binding does not affect receptor conformation.
Therefore, the S10-1 peptide has no direct effect on the
receptor on its own, but sensitizes K1-positive cells to
FasL (Figure 1A) by displacing the K1 protein
(Additional file 1: Figure S2). The S20-3 peptide, more
rigid and bulkier that S10-1peptide, can bind Fas only
in the absence of K1. Without the flanking domains of
the K1 protein and the whole Ig-like domain, S20-3
(and S20-2) can bind Fas receptor similarly to S10-1,
but the presence of additional residues/structures
induces conformational change mimicking the active
state of the receptor.
The extrinsic apoptotic pathway involves activation of
death receptors, recruitment of FADD, cleavage of pro-
caspase-8, activation of caspases' cascade, and a drop in
mitochondrial membrane potential [1]. While the pre-
cise target for the cell-killing activity of the S20-3 pep-
tide is unclear, data presented here clearly show that the
peptide activates caspase-8, -9, and -3 (Figure 1D) and
decreases mitochondrial membrane potential (Additional
file 1: Figure S1), suggesting involvement of a death re-
ceptor, such as Fas. However, a conventional dose of the
pancaspase inhibitor z-VAD blocked cell killing only in-
completely (Figure 3B), and Jurkat cells with mutated in-
active caspase-8 or dominant-negative FADD also
showed only partial blockage of S20-3–induced cell-kill-
ing (Figure 3A), despite their inability to form the death-inducing signaling complex (DISC) [23]. This persistence
of the S20-3 peptide to kill mutant Jurkat cells
(Figure 3A), the killing of Daudi cells that are considered
Fas-resistant [17,24], the increase of necrotic death in
the z-VAD-treated Daudi cells (Figure 3C and Additional
file 1: Figure S3A), and their relatively fast killing [nec-
rotic cell death in Daudi cells was detectable 1 hour after
peptide exposure (Additional file 1: Figure S3)] sug-
gested to us that S20-3 also activates a TNF receptor.
Even though Fas belongs to the TNF receptor family
and shares a significant structural similarity with TNFR
[19], the outcomes of activating these receptors can be
quite different [25]. For example, activation of Fas recep-
tor in L929 cells triggers apoptosis, whereas activation of
TNFR triggers necrosis [26]. Owing to the structural
similarity, TNF-α is able to also bind and activate the
Fas receptor [20]. We, thus, investigated the possibility
that, because of the structural promiscuity (further sup-
ported by the killing properties of a structurally related
TCR peptide), the S20-3 peptide designed to bind the
Fas receptor may also bind TNFR and trigger necrosis.
We detected TNFRI expression in BJAB, Jurkat, and
Daudi cells (Figure 3), and the TNFRI-blocking antibody
significantly inhibited S20-3– and TNF-α–induced cell
killing in all 3 cell lines (Figure 4B and C). On the con-
trary, the TNFRII-blocking antibody showed no inhibi-
tory effect on the S20-3 cell-killing of TNFRII-positive
Daudi cells (Figure 4B). This finding is not surprising
considering the fact that activation of TNFRII triggers
pro-survival signaling in hematological cancer cells [22],
and activation of TNFRI is required for any death signal-
ing from TNFRII due to the lack of a death domain in
TNFRII [27].
Our results with FADD– and caspase-8–defective Jur-
kat cells are in agreement with the reports showing that
under apoptosis-deficient conditions (such as non-
functional caspase-8 or FADD), stimulation with FasL or
TNF-α could induce cell death with morphological fea-
tures of necrosis/necroptosis [21,28,29]. Furthermore,
lack of FADD, but not of caspase-8, was shown to
sensitize Jurkat cells to TNF-α–induced necrosis [30].
Smac mimetic BV6 enhanced TNF-induced cell death in
leukemia cells in 2 different ways: necroptosis, when the
cells were apoptosis resistant (FADD– and caspase-8–
deficient), and caspase-8–dependent apoptosis in
apoptosis-proficient cells [31].
We hypothesize that the different death pathways can
be activated in response to S20-3 treatment in Jurkat,
Daudi, and BJAB cells, depending on the availability of
and sensitivity to Fas and TNFRs. Another possibility is
a cross talk between signaling events from TNF and Fas
receptors, as reported by Takada et al., in which TNFRI
is recruited by Fas to induce apoptosis [32].
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peptide activity seemed to be specific to malignant cells;
leukemia T cells displayed a much greater sensitivity to
S20-3 than nonmalignant cells (Figure 2C). While the
constitutive expression of TNF receptors was clearly
demonstrated in most tumor cells, in normal peripheral
lymphocytes, the expression of TNF receptors is sub-
jected to a positive and negative regulation and can be
induced by different stimuli [33,34]. However, normal
unstimulated PBMCs express very low amounts of
mRNAs for TNFRII >TNFRI > Fas [35], and normal lym-
phocytes were shown to be resistant to stimulation with
activating antibodies targeting TNFRI, TNFRII, or Fas
[36]. Thus, our findings of cancer-specific killing by the
S20-3 peptide are in agreement with these reports.
Conclusions
This is the first report where a peptide derived from the
Ig-like domain of the virus-encoded protein effectively
induces cell death, specifically in human lymphoma and
leukemia cells with minimal toxicity to normal PBMCs
and, thus, may expose a novel alternative to conven-
tional chemotherapy, which may also be applied to other
cancer types.
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